Prognostic variables in node-negative and node-positive breast cancerGiampietro Gasparini Springer Science & Business Media, 28 feb 1999 - 428 páginas During the last decade, important advancements on the understanding of the molecular mechanisms involved in tumorigenesis and progression of breast cancer have been made, particularly regarding the mechanisms of control of the cell cycle, apoptosis, metastasis, and angiogenesis. Translation of basic research to the clinical setting by the identification of assessable markers associated with the above biological mechanisms has permitted verification of the clinical significance of several prognostic indicators and has highlighted the heterogeneous nature of invasive breast cancer.Reprinted from Breast Cancer Research And Treatment, this text contains original papers, overviews, and position papers on the methodological aspects and the clinical significance of the more interesting prognostic and predictive indicators. Ultimately, the determination of biological prognostic and predictive markers with easily applicable, reproducible, and standardizable assays is an integral part of future research aimed to improve the management of patients operated for breast cancer in the years to come. Novel therapeutic strategies based not only on chemotherapy or hormone therapy, but directed at interfering with the molecular targets involved in tumor progression and metastasis, warrant clinical testing and are a major challenge to enhance the potential cure of breast cancer. |
Índice
Prognostic variables in nodenegative and nodepositive breast cancer Introduction | 1 |
Routinely available indicators of prognosis in breast cancer | 3 |
Prognostic factors for patients with breast cancers 1cm and smaller | 17 |
Steroid hormone receptors in breast cancer management | 35 |
Sphase fraction combined with other patient and tumor characteristics for the prognosis of nodenegative estrogenreceptorpositive breast cancer | 47 |
Sphase fraction and breast cancer a decade of experience | 63 |
Prognostic and predictive value of thymidine labelling index in breast cancer | 75 |
Cyclin Dl in breast cancer | 91 |
The 67 kDa laminin receptor as a prognostic factor in human cancer | 225 |
Assessment of intratumoral vascularization angiogenesis in breast cancer prognosis | 235 |
Clinical significance of angiogenic factors in breast cancer | 247 |
Insulinlike growth factors in human breast cancer | 263 |
Molecular prognostic markers in breast cancer | 273 |
Prognostic significance of micrometastatic bone marrow involvement | 289 |
Timing of surgery for primary breast cancer with regard to the menstrual phase and prognosis1 | 305 |
cancer | 315 |
Cyclins and breast cancer | 107 |
Prognostic implications of expression of the cell cycle inhibitor protein p27Klpl | 119 |
new ligands and receptors and their role in breast cancer | 133 |
cerbB2 expression predicts tamoxifen efficacy in breast cancer patients | 145 |
HER2neu as a predictive marker of response to breast cancer therapy | 155 |
Prognostic and predictive value of p53 and p21 in breast cancer | 169 |
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer | 187 |
Metalloproteinases and tissue inhibitors of metalloproteinases | 201 |
Matrix metalloproteinase inhibitors | 213 |
Accepted utilities and novel prospects | 327 |
The relationship between prognostic and predictive factors in the management of breast cancer | 349 |
Methodological challenges in the evaluation of prognostic factors in breast cancer | 377 |
When is statistically significant clinically useful? | 393 |
Prognostic variables in nodenegative and nodepositive breast cancer editorial | 409 |
Author index page numbers at the bottom of the page | 421 |
Otras ediciones - Ver todo
Prognostic variables in node-negative and node-positive breast cancer Giampietro Gasparini Vista previa restringida - 2012 |
Prognostic variables in node-negative and node-positive breast cancer Giampietro Gasparini No hay ninguna vista previa disponible - 2012 |
Prognostic variables in node-negative and node-positive breast cancer Giampietro Gasparini No hay ninguna vista previa disponible - 2012 |
Términos y frases comunes
adjuvant therapy analysis angiogenesis antibody antigen assay associated axillary lymph node Biol biological breast cancer breast cancer cells breast cancer patients Breast Cancer Res breast carcinoma c-erbB2 Cancer Res Treat cell cycle cell lines chemotherapy Clin Oncol clinical correlation cutpoints cyclin D1 cyclin E detected disease endothelial estrogen receptor evaluated expression follow-up gene grade growth factor receptor hazard ratio HER2/neu histologic human breast cancer IGF1R immunohistochemical inhibitor kinase laminin lesions levels ligand mammary matrix metalloproteinase metalloproteinase metastasis metastatic metastatic breast cancer microvessel count Natl Cancer Inst negative node-negative node-negative breast cancer node-positive Oncogene outcome overall survival overexpression Pathol ploidy predictive factors primary breast cancer prog prognostic and predictive prognostic factors prognostic markers prognostic significance prognostic value proliferation protein recurrence relapse response S-phase fraction studies surgery tamoxifen tissue treatment trials tumor cells tumor markers variables vascular